Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

vTv Therapeutics Inc (VTVT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow vTv Therapeutics Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
25.500 +0.520    +2.08%
16:00:59 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 5,220
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 25.000 - 25.975
vTv Therapeutics Inc 25.500 +0.520 +2.08%

vTv Therapeutics Inc Company Profile

 
Get an in-depth profile of vTv Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

16

Equity Type

ORD

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company’s other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Contact Information

Address 3980 Premier Drive Suite 310
High Point, 27265
United States
Phone 336 841 0300
Fax 336 841 0310

Top Executives

Name Age Since Title
Keith Reginald Harris 71 2022 Independent Director
Srinivas Akkaraju 56 2024 Independent Director
Anne M. Phillips 70 2024 Independent Director
Paul J. Sekhri 66 2022 CEO, President & Chairman of the Board
Richard S. Nelson 54 2020 Executive VP of Corporate Development & Director
Fahed Al-Marzooqi 45 2022 Independent Director
Raymond Cheong 42 2024 Lead Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VTVT Comments

Write your thoughts about vTv Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Gerard Gustafson
Gerard Gustafson Nov 29, 2023 10:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What just happened today?
Rami Bakeir rbakeir
Rami Bakeir rbakeir May 03, 2022 9:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hoax
Lior Liv
Lior Liv Sep 24, 2021 9:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to buy and sell at 2.5
Name Last Name
Name Last Name Sep 24, 2021 6:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
slide to 2 after openning
Simone DeglInnocenti
Simone DeglInnocenti May 06, 2021 1:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good morning everyone, is there someone so kind who has the desire and time to explain to a layman from Florence (Italy), what is the meaning of the form k8 just presented by vtvt? Thanks in advance
Bips Bar
Bips Bar May 06, 2021 1:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission (SEC).
Bips Bar
Bips Bar May 06, 2021 1:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Filing a Form 8-K will often impact a company's stock. Which way the stock moves will depend on the nature of the news being disclosed.
Feed Seow
Feed Seow Apr 13, 2021 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is this a 5 target?
Gorilla Squad
Gorilla Squad Apr 13, 2021 11:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news ! Buy and hold 🚀🚀
Matt Stone
Matt Stone Feb 04, 2021 10:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let's go!
Melissa Ellis
Melissa Ellis Dec 16, 2020 9:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow, how long will it keep going down you 🤔 think?
Giuseppe Giannachi
Giuseppe Giannachi Dec 16, 2020 8:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow... any news?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email